Table 1.

Patient characteristics

Age (yr), median (range)	51 (34–69)
Females, %	100
Race, n (%)
Caucasian	11 (91.7)
Black/African-American	1 (8.3)
Disease duration (yr), median (range)	8.0 (2–18)
Ocular symptoms, n (%)	12 (100)
Oral symptoms, n (%)	12 (100)
Ocular signs, n (%)	12 (100)
Schimer-I test score, mm, median (range)
OD	11 (0–35)
OS	5 (0–19)
Lissamine green staining test score (0–18), median (range)
OD	9.0 (2–18)
OS	9.5 (4–18)
Unstimulated WSF rate, mL/min, median (range)	0.025 (0.0–0.22)
Stimulated WSF rate, mL/min, median (range)	0.05 (0.0–0.65)
Labial minor salivary gland focus score ≥1 per 4 mm2, n	3/4
Fatigue (VAS > 50 mm), n (%)	10 (83.3)
Joint pain (VAS > 50 mm), n (%)	9 (75.0)
Severe parotid gland swelling, n (%)	3 (25.0)
Other extraglandular disease, n (%)
Peripheral neuropathy	4 (33.3)
Interstitial lung disease	1 (8.3)
Anti-Ro (SSA) antibodies, n (%)	10 (83.3)
Anti-La (SSB) antibodies, n (%)	5 (41.7)
Rheumatoid factor, n (%)	10 (83.3)
SF-36, median (range)
Physical function	60.0 (20, 100)
Mental function	70.0 (60, 90)

Abbreviations: WSF=whole salivary flow; VAS=visual analog scale; OD=right eye; OS=left eye